Research output per year
Research output per year
Fingerprint
Dive into the research topics where Sajid Khan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer
Khan, S., Cao, L., Wiegand, J., Zhang, P., Zajac-Kaye, M., Kaye, F. J., Zheng, G. & Zhou, D., Mar 2024, In: Cells. 13, 6, 528.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
Khan, S., Kellish, P., Connis, N., Thummuri, D., Wiegand, J., Zhang, P., Zhang, X., Budamagunta, V., Hua, N., Yang, Y., De, U., Jin, L., Zhang, W., Zheng, G., Hromas, R., Hann, C., Zajac-Kaye, M., Kaye, F. J. & Zhou, D., Dec 2023, In: Cell Death Discovery. 9, 1, 1.Research output: Contribution to journal › Article › peer-review
Open Access13 Scopus citations -
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
Khan, S., Budamagunta, V. & Zhou, D., Jan 2023, Pancreatic Cancer: Basic Mechanisms and Therapies. Emdad, L., Atfi, A., Gogna, R., Trevino, J. G. & Fisher, P. B. (eds.). Academic Press Inc., p. 145-184 40 p. (Advances in Cancer Research; vol. 159).Research output: Chapter in Book/Report/Conference proceeding › Chapter
7 Scopus citations -
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., Zajac-Kaye, M., Kaye, F. J., Zheng, G. & Zhou, D., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 23.Research output: Contribution to journal › Letter › peer-review
Open Access26 Scopus citations -
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., Khan, S., Zhang, X., Hua, N., Yang, Q., Arango, S., Zhang, W., Nayak, D., Olsen, S. K., Weintraub, S. T. & Hromas, R. & 4 others, , Dec 2021, In: Nature communications. 12, 1, 6896.Research output: Contribution to journal › Article › peer-review
Open Access72 Scopus citations
Datasets
-
Additional file 2 of Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12726547, https://springernature.figshare.com/articles/dataset/Additional_file_2_of_Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/12726547
Dataset
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.c.5075029, https://springernature.figshare.com/collections/Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/5075029
Dataset
-
Additional file 3 of Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12726550, https://springernature.figshare.com/articles/dataset/Additional_file_3_of_Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/12726550
Dataset
-
Additional file 3 of Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12726550.v1, https://springernature.figshare.com/articles/dataset/Additional_file_3_of_Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/12726550/1
Dataset
-
Additional file 2 of Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y. (Creator), Khan, S. (Creator), Huo, Z. (Creator), Lv, D. (Creator), Zhang, X. (Creator), Liu, X. (Creator), Yuan, Y. (Creator), Hromas, R. (Creator), Xu, M. (Creator), Zheng, G. (Creator) & Zhou, D. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12726547.v1, https://springernature.figshare.com/articles/dataset/Additional_file_2_of_Proteolysis_targeting_chimeras_PROTACs_are_emerging_therapeutics_for_hematologic_malignancies/12726547/1
Dataset